Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

Genetic vaccination with adenoviral (Ad) gene transfer vectors requires transduction of professional antigen-presenting cells. However, because the natural Ad receptors are expressed on many cell types, the Ad vectors currently in use are characterized by high promiscuity. In fact, the majority of injected Ad vector particles are likely to transduce non-target cells. We have analyzed various sizes of polyethylene glycol (PEG) molecules for vector particle detargeting, and our data provide evidence that the size of the PEG determines detargeting efficiency. With the use of appropriately large PEG molecules, vector particles were detargeted from muscle after local delivery and from liver after systemic delivery in mouse models. Surprisingly, fully detargeted PEGylated Ad vectors still induced strong cellular and humoral immune responses to vector-encoded transgene products. Also, injection of PEGylated and non-PEGylated vector particles resulted in similar kinetics of transgene product-specific cytotoxic immune responses, thereby suggesting that the same cell types were involved in their induction. Furthermore, we showed that PEGylated vectors evade neutralizing anti-Ad antibodies in vivo. This feature might help circumvent the recognized limitation imposed by the widespread occurrence of anti-Ad immunity in the human population. We suggest that PEGylated Ad particles with significantly reduced promiscuity may qualify as a novel and safe vector format for genetic vaccination.

• Publication year

  2008

• Venue

  Molecular Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/SJ.MT.6300306PMID 17848961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors

  2007cited by this paper
• Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells

  2006cited by this paper
• Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

  2006cited by this paper
• Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosis

  2006cited by this paper
• Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

  2006cited by this paper
• Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

  2006cited by this paper
• Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.

  2005cited by this paper
• Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.

  2005cited by this paper
• Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

  2005cited by this paper
• Elimination of Innate Immune Responses and Liver Inflammation by PEGylation of Adenoviral Vectors and Methylprednisolone

  2005cited by this paper
• Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1

  2005cited by this paper
• Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus1

  2005cited by this paper
• PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

  2005cited by this paper
• Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1

  2004cited by this paper
• Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats

  2004cited by this paper
• Adenoviruses as vaccine vectors

  2004cited by this paper
• Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

  2003cited by this paper
• Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

  2003cited by this paper
• Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells.

  2003cited by this paper
• A DNA-Based Method to Assay Total and Infectious Particle Contents and Helper Virus Contamination in High-Capacity Adenoviral Vector Preparations

  2002cited by this paper
• PEGylation of E1-Deleted Adenovirus Vectors Allows Significant Gene Expression on Readministration to Liver

  2002cited by this paper
• Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ

  2002cited by this paper
• “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung

  2001cited by this paper
• Efficient Transformation of Primary Human Amniocytes by E1 Functions of Ad5: Generation of New Cell Lines for Adenoviral Vector Production

  2000cited by this paper
• The liver as a site of T‐cell apoptosis: graveyard, or killing field?

  2000cited by this paper
• DNA vaccines: immunology, application, and optimization*.

  2000cited by this paper
• Ongoing Murine T1 or T2 Immune Responses to the Hepatitis B Surface Antigen Are Excluded from the Liver that Expresses Transgene-Encoded Hepatitis B Surface Antigen1

  2000cited by this paper
• Development of a Rapid Method for the PEGylation of Adenoviruses with Enhanced Transduction and Improved Stability under Harsh Storage Conditions

  2000cited by this paper
• PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo

  1999cited by this paper
• Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo

  1999cited by this paper
• Modification of an Adenoviral Vector with Biologically Selected Peptides: A Novel Strategy for Gene Delivery to Cells of Choice

  1999cited by this paper
• Selective retention of activated CD8+ T cells by the normal liver.

  1999cited by this paper
• Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset

  1999cited by this paper
• Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma

  1998cited by this paper

• Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8+ T cell responses

  2025cites this paper
• Developing the next-generation of adenoviral vector vaccines

  2025cites this paper
• The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies

  2024cites this paper
• Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges

  2024cites this paper
• Emerging delivery strategy for oncolytic virotherapy

  2024cites this paper
• Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity

  2023cites this paper
• Progress in oncolytic viruses modified with nanomaterials for intravenous application

  2023cites this paper
• Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy

  2022cites this paper
• Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics

  2022cites this paper
• Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses

  2022cites this paper
• Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector–Host Interactions

  2021cites this paper
• Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors

  2021cites this paper
• Improved Functionality of Exhausted Intrahepatic CXCR5+ CD8+ T Cells Contributes to Chronic Antigen Clearance Upon Immunomodulation

  2021cites this paper
• Materials promoting viral gene delivery.

  2020cites this paper
• Live long and active: Polypeptide-mediated assembly of antibody variable fragments.

  2020cites this paper
• Retargeting adenoviruses for therapeutic applications and vaccines

  2020cites this paper
• Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses

  2020cites this paper
• Exploring the Functions of Polymers in Adenovirus-Mediated Gene Delivery: Evading Immune Response and Redirect Tropism

  2019cites this paper
• Exploring the Functions of polymers in adenovirus-mediated gene delivery: evading immune response and redirecting tropism.

  2019cites this paper
• Therapeutic application of the CRISPR system: current issues and new prospects

  2019cites this paper
• Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity

  2019cites this paper
• Facile Nanolization Strategy for Therapeutic Ganoderma Lucidum Spore Oil to Achieve Enhanced Protection against Radiation-Induced Heart Disease.

  2019cites this paper
• Capsid protein functions of enteric human adenoviruses

  2018cites this paper
• Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

  2018cites this paper
• Advances in oncolytic adenovirus therapy for pancreatic cancer.

  2018cites this paper
• Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector–Host Interactions for Therapy

  2017cites this paper
• Chapter 14 – Gene Therapy

  2017cites this paper
• Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

  2017cites this paper
• Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5

  2017cites this paper
• TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

  2017cites this paper
• Antibodies against Adenoviruses

  2016cites this paper
• High Aspect Ratio Viral Nanoparticles for Cancer Therapy

  2016cites this paper
• Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.

  2016cites this paper
• Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy

  2016cites this paper
• Adenovirus-host interactions : implications for tropism and therapy

  2016cites this paper
• Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.

  2016cites this paper
• Polymeric oncolytic adenovirus for cancer gene therapy.

  2015cites this paper
• Hexon Modification to Improve the Activity of Oncolytic Adenovirus Vectors against Neoplastic and Stromal Cells in Pancreatic Cancer

  2015cites this paper
• Effects of cell-penetrating peptides on transduction efficiency of PEGylated adenovirus.

  2015cites this paper
• Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X.

  2015cites this paper
• Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.

  2015cites this paper
• Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls

  2015cites this paper
• Real-Time Monitoring Surface Chemistry-Dependent In Vivo Behaviors of Protein Nanocages via Encapsulating an NIR-II Ag2S Quantum Dot.

  2015cites this paper
• VSV-GP: a Potent Viral Vaccine Vector That Boosts the Immune Response upon Repeated Applications

  2014cites this paper
• Viral hybrid-vectors for delivery of autonomous replicons.

  2014cites this paper
• Adenovirus-Based Vaccines for Fighting Infectious Diseases and Cancer: Progress in the Field

  2014cites this paper
• Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1.

  2014cites this paper
• Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo

  2014cites this paper
• A targeting peptide improves adenovirus-mediated transduction of a glioblastoma cell line.

  2014cites this paper
• Overview of nano-drugs characteristics for clinical application: the journey from the entry to the exit point

  2014cites this paper
• TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

  2014cites this paper
• Molecular delivery of plasmids for genetic vaccination.

  2013cites this paper
• Aptamer modification improves the adenoviral transduction of malignant glioma cells.

  2013cites this paper
• Foamy virus‐adenovirus hybrid vectors for gene therapy of the arthritides

  2013cites this paper
• Aptamer modification improves the adenoviral transduction of malignant glioma cells.

  2013cites this paper
• Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

  2013cites this paper
• Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery.

  2012cites this paper
• A Transductionally Retargeted Adenoviral Vector for Virotherapy of Her2/neu-Expressing Prostate Cancer

  2012cites this paper
• Polymer coatings for delivery of nucleic acid therapeutics.

  2012cites this paper
• A hexon-specific PEGylated adenovirus vector utilizing blood coagulation factor X.

  2012cites this paper
• Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

  2012cites this paper
• Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy.

  2012cites this paper
• Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus

  2012cites this paper
• Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting

  2011influential citation
• ΔE1 and high‐capacity adenoviral vectors expressing full‐length codon‐optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum

  2011cites this paper
• Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

  2011cites this paper
• Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.

  2011cites this paper
• Delivery of antigens by viral vectors for vaccination.

  2011cites this paper
• Adenoviral vector immunity: its implications and circumvention strategies.

  2011cites this paper
• High‐capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product‐directed CD8 T‐cell responses

  2011cites this paper
• Current targeting strategies for adenovirus vectors in cancer gene therapy.

  2011cites this paper
• miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

  2011cites this paper
• Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction.

  2011cites this paper
• A recombinant myeloid-binding adenovirus for targeted pulmonary gene therapy

  2011cites this paper
• Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.

  2011cites this paper
• Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity

  2010cites this paper
• Gene Transfer Vectors Targeted to Human Prostate Cancer: Do We Need Better Preclinical Testing Systems?

  2010cites this paper
• PEGylated Adenoviruses: From Mice to Monkeys

  2010influential citation
• Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer.

  2010cites this paper
• An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood

  2010cites this paper
• Capsomer-Specific Fluorescent Labeling of Adenoviral Vector Particles Allows for Detailed Analysis of Intracellular Particle Trafficking and the Performance of Bioresponsive Bonds for Vector Capsid Modifications

  2010cites this paper
• Chemical Conjugation of Cowpea Mosaic Viruses with Reactive HPMA-Based Polymers

  2010cites this paper
• Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy

  2010cites this paper
• Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors

  2010cites this paper
• Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration.

  2010cites this paper
• Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors

  2009cites this paper
• Transductional retargeting of human adenovirus type 5 to ανβ6 integrin for cancer gene therapy

  2009cites this paper
• Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus

  2009influential citation
• Two key challenges for effective adenovirus-mediated liver gene therapy: innate immune responses and hepatocyte-specific transduction.

  2009cites this paper
• Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis

  2009cites this paper
• Strategies to overcome host immunity to adenovirus vectors in vaccine development

  2009cites this paper
• PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo.

  2009cites this paper
• The influence of innate and pre‐existing immunity on adenovirus therapy

  2009cites this paper
• Targeting of adenovirus gene transfer vectors via combined geneti-chemical modification of the minor capsid protein IX

  2008cites this paper
• Novel strategies in tailoring human adenoviruses into therapeutic cancer gene therapy vectors

  2008cites this paper
• Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.

  2008cites this paper
• Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression.

  2008cites this paper
• Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses

  2008influential citation
• The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.

  2008cites this paper
• Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides

  2008cites this paper